Hikma Pharmaceuticals Public annual operating cash flow
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Operating Cash Flow Growth & History (HIK)
Hikma Pharmaceuticals Public's operating cash flow was $436.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $436.0M | −$128.0M | −22.70% |
| 2024 | 2024-12-31 | $564.0M | −$44.0M | −7.24% |
| 2023 | 2023-12-31 | $608.0M | $78.0M | +14.72% |
| 2022 | 2022-12-31 | $530.0M | −$108.0M | −16.93% |
| 2021 | 2021-12-31 | $638.0M | $174.0M | +37.50% |
| 2020 | 2020-12-31 | $464.0M | — | — |
Hikma Pharmaceuticals Public operating cash flow trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's operating cash flow decreased from $464.0M to $436.0M, a change of −$28.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company official filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...